Printed from Voxsanity (voxsanity.com.au) — NCT06121284 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Depression And Anxiety
Phase 2 Depression and Anxiety Trial, Recruiting
NCT06121284
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 24 years
- People of any sex or gender
- People who are able to make their own informed decision about taking part in a treatment study
- People who have previously attempted suicide, as assessed using a specific clinical scale called the Columbia Suicide Severity Rating Scale
- People who are currently experiencing thoughts of suicide, as measured by a specific rating scale (people with active plans to act on suicidal thoughts are only considered if they are currently in hospital)
- People with moderate depression, as measured by a score of 15 or higher on a standard depression rating scale called the HAMD-17
- People who are able to follow and attend the treatment schedule
- People who pass a standard safety screening questionnaire used before brain stimulation treatments
- People who have had normal results on heart and blood tests (including kidney and liver function tests) within the past month
Who may not be able to join:
- People with a known allergy to the medication cycloserine or any of its ingredients
- People who are currently misusing alcohol or other substances
- People who currently have, or have a history of, psychosis (a condition involving a break from reality)
- People who are currently pregnant, breastfeeding, or planning to become pregnant during the study — the trial requires that people who could become pregnant use highly effective contraception or a double barrier method throughout the study (abstinence is only accepted when it is that person's usual and preferred lifestyle)
- People who have already tried electroconvulsive therapy (ECT) during this current period of illness without it helping (previous ECT during a different episode does not affect eligibility)
- People who have previously tried repetitive transcranial magnetic stimulation (rTMS) without it helping
- People with a significant neurological condition or brain injury, including a history of epilepsy, cerebral aneurysm, Parkinson's disease, Huntington's disease, multiple sclerosis, or a serious head injury involving loss of consciousness for 15 minutes or more
- People with a serious unstable physical health condition, or who have a cardiac pacemaker or an implanted medication pump
- People who have metal implants inside or near the head (such as aneurysm clips, brain stimulators, cochlear implants, or shunts), or any other metal objects near the head that cannot be safely removed
- People currently taking certain medications that affect brain chemistry, including benzodiazepines, gabapentin, pregabalin, or anticonvulsant medications, as these may reduce how well the brain stimulation treatment works
- People with any history of metal fragments anywhere in the body, particularly near the eyes (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Alexander McGirr, MD PhD, University of Calgary
Phone: 403 210 6410
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Phase 2
Sponsor
University of Calgary
Registry
ClinicalTrials.gov
Start date
11 March 2024
Est. completion
1 July 2026
Where this trial is recruiting
🇨🇦 Canada
Primary endpoints
Performance on the Death Implicit Association Test (D-IAT) at treatment end
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.